A measure of the proportion of treatment effect explained by a surrogate marker

Biometrics

Volumn 58, Issue 4, 2002, Pages 803-812

  Wang, Yue ^a   Taylor, Jeremy M G ^a  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Surrogate marker; Validation

Indexed keywords

MEDICAL APPLICATIONS;

CLINICAL TRIAL; DURATION TIME; LONG DURATION; QUANTITATIVE MEASURES; RANDOMIZED CLINICAL TRIALS; REGRESSION COEFFICIENT; SIMULATION STUDIES; SURROGATE MARKER; TREATMENT EFFECTS; VALIDATION;

STATISTICS;

BIOMETRY;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA ANALYSIS; DISEASE MARKER; OUTCOMES RESEARCH; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 0036966524     PISSN: 0006341X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0006-341X.2002.00803.x     Document Type: Article

References (17)

1. Buyse, M. and Molenberghs, G. (1998). Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 54, 1014-1029.
2. Buyse, M., Molenberghs, G., Burzykowski, T., Renard, D., and Geys, H. (2000). Validation of surrogate endpoints in meta-analysis of randomized experiments. Biostatistics 1, 49-68.
3. Bycott, P. W. and Taylor, J. M. G. (1998). An evaluation of a measure of the proportion of the treatment effect explained by a surrogate marker. Controlled Clinical Trials 19, 555-568.
4. Daniels, M. J. and Hughes, M. D. (1997). Meta-analysis for the evaluation of potential surrogate markers. Statistics in Medicine 16, 1965-1982.
5. DeGruttola, V., Fleming, T. R., Lin, D. Y., and Coombs, R. (1996). Validating surrogate markers: Are we being naive? Journal of Infectious Disease 175, 237-246.
6. Efron, B. and Tibshirani, R. (1986). Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Statistical Science 1, 54-77.
7. Ellenberg, S. S. and Hamilton, J. M. (1989). Surrogate endpoints in clinical trials: Cancer. Statistics in Medicine 8, 405-413.
8. Fleming, T. R. (1992). Evaluating therapeutic interventions: Some issues and experiences. Statistical Science 7, 428-456.
9. Fleming, T. R. and DeMets, D. L. (1996). Surrogate endpoints in clinical trials: Are we being misled? Annals of Internal Medicine 125, 605-613.
10. Freedman, L. S. (2001). Confidence intervals and statistical power of the "validation" ratio for surrogate or intermediate endpoints. Journal of Statistical Planning and Inference 96, 143-153.
11. Freedman, L. S., Graubard, B. I., and Schatzkin, A. (1992). Statistical validation of intermediate endpoints for chronic disease. Statistics in Medicine 11, 167-178.
12. Hwang, G. J. T. (1995). Fieller's problems and resampling techniques. Statistica Sinica 5, 161-171.
13. Lagakos, S. W. and Hoth, D. F. (1992). Surrogate markers in AIDS: Where are we? Where are we going? Annals of Internal Medicine 116, 599-601.
14. Lin, D. Y., Fleming, T. R., and DeGruttola, V. (1997). Estimating the proportion of treatment effect explained by a surrogate marker. Statistics in Medicine 16, 1515-1527.
15. Prentice, R. L. (1989). Surrogate endpoints in clinical trials: Definition and operational criteria. Statistics in Medicine 8, 431-440.
16. Schatzkin, A., Freedman, L. S., Schiffman, M. H., and Dawsey, S. M. (1990). Validation of intermediate end points in cancer research. Journal of the National Cancer Institute 82, 1746-1752.
17. Tsiatis, A. A., DeGruttola, V., and Wulfsohn, M. S. (1995). Modeling the relationship of survival to longitudinal data measured with error: Applications to survival and CD4 counts in patients with AIDs. Journal of the American Statistical Association 90, 27-37.